(Reuters) - Indivior (L:INDV) said on Wednesday the impact from the launch of a generic version of its opioid addiction treatment "could be materially higher" in 2018, as the British drugmaker posted a second straight drop in quarterly profit.
The company, which issued a profit warning this month citing significant market share loss for star drug Suboxone Film, said adjusted net income fell 21.3 percent to $70 million (£53 million) in the quarter ended June 30 from a year earlier.
Revenue fell 6.9 percent to $268 million in the quarter.